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Background: Autism spectrum disorder (ASD) is a neurodevelopmental disorder affecting more than 1% of
children. It is characterized by social communication deficits and repetitive behaviors/restricted interests. In the
absence of any medications known to improve core symptom domains, parents often use complementary
alternative treatments, including omega-3 fatty acid supplements.
Methods: We conducted a 6-month, randomized, placebo controlled trial of omega-3 fatty acid supplements
(1.5 g) vs placebo in children 2 to 5 years of age with ASD. Primary outcome measures included the autism
composite score of the Pervasive Developmental Disorders Behavioral Inventory (PDDBI) and the externalizing
problems score of the Behavior Assessment System for Children (BASC-2). Secondary outcome measures included
clinical global improvement (Clinical Global Impression-Improvement (CGI-I)), adaptive function (Vineland Adaptive
Behavior Scale (VABS-II)), and language gains (Preschool Language Scale (PLS-4)), as well as safety. Exploratory
analysis investigated potential correlations between changes in cytokine profiles and treatment response.
Results: Thirty-eight participants were randomized in a 1:1 fashion. There was no significant difference between
groups on the 0- to 24-week change in PDDBI autism composite scores (p = 0.5). There was a significant group by
week interaction on the BASC-2 externalizing problem score, with participants randomized to the treatment group
demonstrating worsening scores (p = 0.02). There was no statistically significant week by group effect on either
adaptive function (p = 0.09) or language (p = 0.6). Omega-3s were relatively well tolerated. Changes in cytokines
during the study did not significantly correlate with treatment response.
Conclusions: This study does not support high dose supplementation of omega-3 fatty acids in young children
with ASD.
Trial registration: Clinicaltrials.gov NCT01248728. Registered 22 November 2010.
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Autism spectrum disorder (ASD) is a neurodevelop-
mental disorder characterized by social communication
deficits and repetitive behaviors/restricted interests [1].
Although prevalence estimates vary, recent estimates
suggest that 1 in 68 children are diagnosed with ASD in* Correspondence: eanagnostou@hollandbloorview.ca
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unless otherwise stated.the US. The disorder is evident in early childhood and
children often present with a series of co-occurring
symptoms and disorders including externalizing behav-
iors, anxiety, obsessive compulsive symptoms, seizures,
sleep and gastrointestinal complaints, and immune dif-
ferences, among others [2]. There is a paucity of medica-
tions shown to be useful for core symptom domains,
and only two medications have received an Food and
Drug Administration (FDA) indication for the treatment
of associated symptoms in ASD (risperidone and aripi-
prazole for irritability). Within this context, there isl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ments for children with ASD [3], even in the absence of
good quality data to support their use.
Omega-3 fatty acids are a special class of poly-
unsaturated fatty acids and include alpha-linoleic acid
(ALA), docosahexaenoic acid (DHA), and eisosapentae-
noic acid (EPA). DHA and EPA are found in fish oils
whereas ALA is plant-derived. Although it is possible to
convert ALA into DHA and EPA, this process is ex-
tremely inefficient and we mostly depend on dietary in-
take of EPA and DHA; only 5% of ALA is converted to
EPA or DHA in humans [4]. There is accumulating data
to support that EPA and DHA are important for brain
structure and function and have been advocated for
the treatment of multiple neurodevelopmental disorders
including mood disorders, schizophrenia, ADHD, and
ASD. DHA and EPA are orthomolecules; their functional
sites are exclusively cell membranes. The fundamental
importance of DHA for the brain is beyond dispute. The
neurons are continually forming axons and dendritic
extensions with accompanying cell membranes. Growing
membranes must be relatively fluid, and DHA is the most
fluidizing element in cell membranes. Even the synapses
are made from membranes preferentially enriched in
DHA [5]. During the last trimester of fetal life and the first
two years of childhood, the brain undergoes a period of
rapid growth. DHA is required for the development of the
sensory, perceptual, cognitive, and motor neural systems
during the brain growth spurt [6,7]. EPA’s importance for
the brain’s development in utero is unclear, but colostrum
and breast milk do contain EPA [8,9]; it plays a significant
role in brain function, and its derivatives are key reg-
ulators of immune endocrine and cardiovascular func-
tion [10]. Several other mechanisms of action have
been hypothesized for, including change in neurotransmit-
ter binding and gene expression, and anti-inflammatory
actions [11-13].
A series of studies have raised the question of
omega-3 fatty acid deficiency in children with ASD.
Specifically, Vancassel et al. and Bell et al. [14,15] re-
ported lower levels of polyunsaturated fatty acids in-
cluding omega-3 s in children with autism compared
to typically developing healthy controls. Ashwood et al.
[16] failed to replicate that finding in 2006, although
there was some evidence for such a disturbance in
children with a history of regression. The reason for
this variability is unclear, but it suggests the possibil-
ity of altered omega-3 fatty acid levels in at least a
subgroup of children with ASD. In addition, omega-3
fatty acids have been shown to have anti-inflammatory
effects that may include decreasing pro-inflammatory
factors, especially IL6, IL10, and TNF-a, and lowering
microglia activation [17] all of which would be of inter-
est in ASD [18].A series of open label studies have previously sug-
gested potential for therapeutic effects of omega-3 fatty
acids on language and maladaptive behaviors in children
with ASD [15,19,20]. These were followed by three pilot
randomized controlled trials. Amminger et al. [21] pub-
lished a small randomized controlled trial of 1.5 g of fish
oil supplementation for 6 weeks in 13 children with aut-
ism, ages 5 to 17. The study used the Aberrant Behavior
Scale (ABC) as the outcome measure and reported
trends in improving hyperactivity, although no changes
reached statistical significance. Bent et al., [22] reported
on a pilot randomized controlled trial in 27 children,
ages 3 to 8 with ASD, treated for 12 weeks. They also
found a trend for improvement in hyperactivity. In both
studies, no effects were noted across social withdrawal,
irritability, inappropriate speech, or stereotypy as mea-
sured by the ABC [23]. A Cochrane review in 2011 re-
ported no evidence for prescribing omega-3 fatty acids
in children with ASD but noted a trend for improve-
ment in hyperactivity and suggested that early treatment
after diagnosis may be the time window most likely to
provide therapeutic benefit [24]. As such, they reserved
judgment for the treatment of young children until such
studies maybe available. Lastly, Bent et al. [25] re-
ported on an internet-based randomized controlled trial
of omega-3 fatty acids in 5- to 8-year olds with ASD. Con-
sistent with previous studies, a trend towards improve-
ment in hyperactivity was noted, although it did not reach
statistical significance.
Supplementation with omega-3s has been generally
well tolerated. Reported side effects in the pediatric
population include gastrointestinal disturbance, head-
aches, sleep disturbance, fishy breath, and changes in the
texture of the skin [13]. Rare adverse events of omega-3
fatty acids include bruising and bleeding diathesis, as
they can produce hypocoagulant effects [26].
There have been several questions related to appropriate
dosing. Both DHA and EPA seem to be neurologically ac-
tive with DHA being more important for brain structure
in early life and EPA being important for continuing brain
function [6,9]. There has been a wide variety of regimens
employed in clinical trials across multiple neurodevelop-
mental/neuropsychiatric disorders, as described above. In
adults, doses as high as 9.6 g per day have been used, as in
the case of bipolar disorder [27]. The FDA has supported
the use of up to 3 g of omega-3 fatty acids per day in
adults without medical follow-up. Health Canada has pub-
lished a monogram in which they recommend up to 1.5 g
of EPA plus DHA for children ages 1 to 8 years (http://
webprod.hc-sc.gc.ca/nhpid-bdipsn/monoReq.do?id=88).
Given the conflicting data on the potential thera-
peutic effects of omega-3 fatty acids in ASD and un-
answered questions about the timing of treatment, we
proceeded with a pilot randomized controlled trial (RCT)
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ASD.
The primary objective of this study was to assess
whether omega-3 fatty acids (NutraSea HP) are effective
in improving autism symptom severity and externalizing
symptoms in young children with ASD. The secondary
objective was to evaluate the effect of omega-3 fatty
acids on adaptive functioning and language development
and to provide further safety data for the use of omega-
3 s in preschool-aged children.
In an exploratory fashion, the study aimed to assess
whether changes in cytokine levels or omega-3 fatty acid
levels in plasma correlate with treatment response.
Methods
This was a randomized double-blind, placebo controlled
trial of omega-3 fatty acids in the treatment of young
children with ASD. This study was approved by the
Holland Bloorview Research Ethics Board and sponsored
by the Alva foundation. The trial was registered prior to
enrolling participants at clinicaltrials.gov (NCT01248728).
Participants
A total of 38 children (28 males and 10 females), 2 to
5 years of age with ASD were randomized into the study,
between December 2010 and December 2013. The target
sample size of 40 was determined to be adequate to
detect effect sizes of 0.8 or larger at 80% power. Parti-
cipants were recruited from Holland Bloorview Kids
Rehabilitation Hospital clinical autism services and part-
ner service organizations. As per the Helsinki agreement,
and institutional policy, informed consent was obtained
from the parents or guardians of all our participants.
The diagnosis of ASD was established using the DSM-
IV (TR) criteria (diagnosis of Autistic disorder or Asperger
syndrome) supported by the Autism Diagnostic Observa-
tion Schedule (ADOS) [28] and the Autism Diagnostic
Interview - Revised (ADI-R) [29]. Overall cognitive level
was estimated by the Mullen Scales of Early Learning-
AGS edition (MSEL) [30].
Inclusion criteria included a confirmed diagnosis of
ASD, age of 2 to 5 years inclusive, on stable non-
pharmacologic (educational, behavioral, dietary or nat-
ural health product) treatment during the preceding
3 months prior to screening, and a commitment not
to initiate or modify interventions during the period
of the study. Children had to have a normal physical
exam and laboratory tests at screening and parents had to
have adequate English proficiency to complete all study
assessments. Exclusion criteria included a history of
prematurity (less than 35 weeks of gestation), a primary
psychiatric disorder other than ASD, use of psychoactive
medications, history of significant neurologic, hemato-
logical, endocrine, cardiovascular (including any rhythmdisorder), respiratory, renal, hepatic, or gastrointestinal
disease, coagulation deficits, or a known genetic syn-
drome. In addition, participants were excluded if they
had a known allergy to either the omega-3 fatty acids
or placebo components, or if they could not tolerate
venipuncture.
Outcome measures
There were two domains targeted as primary outcomes
in the study: autism symptom severity and externalizing
behaviors. The rational for this choice was that studies
in school-aged children only showed trends for the most
part. Therefore, we hypothesized that if we studied chil-
dren earlier in development, we may have the opportun-
ity to capture larger effect sizes and also potential
developmental effects. As such, we chose a measure of
autism symptomatology and a measure of externalizing
behaviors, both of which are validated in the age group
of interest.
Autism symptom severity was measured by the autism
composite score of the Pervasive Developmental Disorder-
Behavioral Inventory (PDDBI). This is a 188-item extended
parent-rated factor-analyzed scale designed to assess treat-
ment outcome in children ages 2 to 12 with ASD. PDDBI
is one of the few outcome measures that is validated down
to 24 months. It measures both problem behaviors and
appropriate social development skills [31,32]. Administra-
tion time is approximately 30 to 45 min for the extended
form. Its psychometric properties are good and it is con-
sidered to have promise as an outcome measure in clinical
trials in ASD [2]. The autism composite score was used as
the primary outcome measure in this study and the meas-
ure was administered at baseline, week 12, and week 24.
The effect of omega-3 fatty acids on externalizing
behaviors was measured using the Behavior Assessment
System for Children, Second Edition (BASC-2) [33]. This
is an informant rating scale that can be completed by
parents or teachers, although only the parent form was
used in this study. It provides standardized composite
scores on Adaptive Skills, Behavioral Symptoms Index,
Externalizing Problems, and Internalizing Problems. The
externalizing problems subscale was used as the second
primary outcome measure in our study. It has strong re-
liability and validity and has been proposed to be appro-
priate for use in clinical trials in ASD [2]. This measure
was administered at baseline, week 12, and week 24.
Secondary outcome measures included the Vineland
Adaptive Behavior Scales, Second Edition (VABS-II)
[34] at baseline, week 12, and week 24; the Preschool
Language Scale-4 (PLS-4) [35] at baseline and week
24 to minimize burden to the child; and the Clinical
Global Impression-Improvement (CGI-I) scale [36] admi-
nistered at each visit to assess global improvement. The
VABS-II is an informant-based instrument designed to
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and adults from birth to 90 years of age. It measures
behaviors in four domains, Communication, Daily Living
Skills, Socialization, and Motor Skills, and provides an
adaptive behavior composite standard score. It has strong
psychometric properties for both reliability and validity
[34]. The PLS-4 is a standardized language assessment
that provides a global assessment of a child’s language
functioning abilities receptive and expressive language. It
has good psychometric properties and is appropriate for
children from birth to 6 years 11 months of age [35], al-
though its ability to detect small changes in language
acquisition during intervention is not as well established.
The CGI-I scale is a seven-point scale that provides a
clinician rating of global improvement (CGI-I). It requires
the clinician to assess the degree to which the participant’s
illness has improved or worsened relative to a baseline
state before the intervention. Change is rated as 1, very
much improved; 2, much improved; 3, minimally impro-
ved; 4, no change; 5, minimally worse; 6, much worse; or
7, very much worse. The CGI scale is a widely used tool in
pharmacological trials and has been shown to be robustly
sensitive to change in adults and pediatric populations
across a wide range of disorders including ASD [36].
Safety and tolerability were evaluated using the Safety
Monitoring Uniform Report Form (SMURF) [37]. This is
a semi-structured interview that contains a general inquiry,
drug-specific queries, as well as several questions about
daily activities (for example, sleep, appetite, energy level,
bowel and bladder function). This instrument has been
widely used in other ASD-related clinical trials.
In an exploratory fashion, a Clinical Global Impression-
Improvement focused on gastrointestinal (CGI-I-GI) func-
tion was used, and plasma phospholipid omega-3 levels and
a cytokine panel were measured at baseline and week 24.
Randomization
Participants were randomized to the two arms in a 1:1
fashion by the pharmacy, based on a randomization
schedule produced by the study biostatistician. They were
stratified into one of four strata based on the PDDBI score
obtained at screening (four quartiles). Block randomi-
zation using blocks of four was used within each stratum
in order to ensure that the distribution of autism severity
was similar between the two treatment groups. Both re-
search personnel and participants were ‘blinded’ to medi-
cation assignment.
Medication and dosing schedule
Participants started at 0.75 g of EPA +DHA (1.875 ml
once a day) of liquid formulation, either NutraSea HP or
placebo. If this was well tolerated, the dose was doubled
to 1.5 g (3.5 ml) after 2 weeks, as per Health Canada
guidelines for maximum dose for this age group. TheNutraSea HP formulation is a naturally derived fish oil
that is extracted, isolated, and processed to contain
EPA/DHA in the ratio of 3:1. The placebo had the same
physical characteristics as the medication but contained
refined olive oil and medium chain triglycerides. Both
the medication and placebo had a natural lemon flavor.
Stability, as well as contamination and microbial testing,
was done as per Health Canada approvals, during the
course of the study.
Frequency of visits
Participants were seen every 2 weeks for the first 4 weeks
and every 4 weeks after that. A table of visits and assess-
ments is included in Supplementary Materials (Additional
file 1: Table S1).
Blood processing and analysis
Blood was centrifuged at room temperature (approxi-
mately 21°C) at 3,000 rpm for 10 min immediately after
collection. Then, the plasma was aliquoted into cryogenic
vials and stored in a −80°C freezer. At the end of the study,
a set of samples were sent to Dr Bruce J Holub at Univer-
sity of Guelph. The lipids were extracted, and the omega-3
fatty acids (EPA and DHA) in the plasma phospholipid
were analyzed via high performance capillary GLC.
A second set was sent to Dr Jane Foster at McMaster
University. Cytokine levels in plasma were measured
with enzyme-linked immunosorbent assay (ELISA) kits
using standard protocols provided. The kits used were
the Human IFN-gamma Quantikine ELISA Kit, Human
TNF-alpha Quantikine HS ELISA kit, and Human IL-6
Quantikine ELISA Kit from R & D systems (Minneapolis,
USA) and the Human IL-1 beta ELISA and Human IL-10
ELISA kits from Ray Biotech (Norcross, USA).
Statistical analysis
We calculated the mean, its standard error, and range by
treatment group across the following potential con-
founders: age, MSEL, ADOS, and ADI-R scores. Because
of our small sample, we did not rely on statistical signifi-
cance to compare the two groups but rather examined
the distributions qualitatively to determine whether or
not there was any evidence of clinically significant group
differences that could impact on our results. We con-
trolled for sex in our models despite similar distributions
in our two groups because of the known association be-
tween sex and externalizing behaviors. This served to re-
duce the error term in our model, enhancing our power
to detect treatment differences.
For the PDDBI, BASC-2, and VABS-II, the change
from baseline to weeks 12 and 24 was analyzed using a
mixed model regression analysis, with baseline scores
and sex in the model as potential confounders. Each
analysis had one within person factor (time), and one
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time × treatment group interaction term was included in
the model to allow the estimation of group differences
in the change from baseline to week 24. For PLS-4, no
week 12 data were collected, so a simple linear regres-
sion of change from baseline to week 24 controlling for
baseline and sex was used to evaluate the group effect.
For the CGI, participants were classified as responders
(CGI ≤2) or non-responders (CGI >2). These groups were
then compared using a basic 2 × 2 (group × responder)
Fisher’s exact test.
The severity of adverse events (AE) for the most se-
vere adverse event over the study period was obtained
for each participant, and its distribution was compared
between the two groups using a Fisher’s exact test. Simi-
larly, the probability of association with treatment was
obtained for the event with the highest probability of
being associated with treatment for each participant and
compared between groups. Finally, the number of partic-
ipants who experienced at least one event within each
event type was also compared between the two groups.
Lastly, we calculated the difference between pre-and
post-study levels of cytokine and fatty acids to report on
their correlation with the pre- and post-study difference
in the primary outcomes.
Results
Patient characteristics
A total of 101 children were initially screened by tele-
phone, and 44 were invited to be screened in person. SixTable 1 Baseline characteristics
Placebo (n = 19, 13 males, 6 females
Mean (minimum-maximum) 95
Age (years) 3.5 (2.0 to 6.0) 3.0
ADOS
Communication (C) 5.5 (3.0 to 9.0) 4.6
Social interaction (SI) 9.5 (6.0 to 14.0) 8.4
Communication (C) + social
interaction (SI)
15.0 (9.0 to 22.0) 13.
ADI-R
Communication 17.2 (5.0 to 28.0) 14.
Social interaction 12.5 (7.0 to 23.0) 10.
Play 6.2 (2.0 to 10.0) 5.1
Stereotyped behavior 4.1 (3.0 to 5.0) 3.7
Mullen scales of early learning-AGS
Visual reception 30.8 (20.0 to 63.0) 23.
Fine motor 28.3 (19.0 to 65.0) 21.
Receptive language 28.8 (19.0 to 56.0) 22.
Expressive language 26.8 (19.0 to 44.0) 22.
Blood omega levels 4.7 (3.4 to 6.2) 4.1of these children either did not meet the criteria or had
personal reasons not to participate in the study; thus 38
children were randomized in a 1:1 fashion. The mean
age of children in the placebo group was 3.5 ± 1.1, and
that in the omega-3 group was 3.8 ± 1.0. The majority of
enrolled children were male (13/19 in the placebo group,
and 15/19 in the omega-3 group). There was no cli-
nically significant difference in baseline characteristics
(Table 1, Additional file 2: Table S2). One participant
dropped out of treatment in the placebo group due to
time constraints at week 12 but participated in an end of
study assessment. A second participant dropped out of
the placebo treatment due to an adverse event (AE) at
week 2. In the medication group, four children did not
complete the study. Two withdrew from treatment due
to personal reasons, one due to an AE, and one withdrew
to explore other treatment options as he experienced no
benefit. Two provided end of study assessments and two
did not (Figure 1).
Clinical outcomes
Primary outcomes
There was no significant difference between groups on
the 0- to 24-week change in PDDBI autism composite
scores (df = 43.4, t = −0.82, p = 0.5, 95% CI = −3.3 to 7.0)
(Table 2, Figure 2). However, there was a significant
group by week interaction on the BASC-2 externalizing
problem score, with participants randomized to placebo
showing a mild improvement (mean change = −3.0 points
from baseline), whereas the treatment group demonstrated) Omega (n = 18, 14 males, 4 females)
% CL for mean Mean (minimum-maximum) 95% CL for mean
to 4.0 3.9 (2.0 to 4.2) 3.4 to 4.4
to 6.5 5.5 (1.0 to 8.0) 4.6 to 6.5
to 10.6 10.7 (4.0 to 14.0) 9.2 to 12.1
1 to 16.9 15.2 (5.0 to 22.0) 12.5 to 17.9
3 to 20.1 19.4 (9.0 to 29.0) 16.7 to 22.2
5 to 14.5 12.8 (9.0 to 20.0) 11.4 to 14.2
to 7.2 5.6 (2.0 to 10.0) 4.7 to 6.4
to 4.5 4.1 (1.0 to 5.0) 3.6 to 4.6
5 to 38.2 31.7 (19.0 to 65.0) 24.3 to 39.1
9 to 34.6 23.6 (19.0 to 41.0) 20.2 to 27.1
4 to 35.1 27.6 (19.0 to 62.0) 21.5 to 33.7
8 to 30.8 25.7 (19.0 to 45.0) 21.2 to 30.3
to 5.3 5.5 (3.9 to 8.2) 4.5 to 6.6
Figure 1 CONSORT flow chart showing the distribution of participants during the study.
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from baseline), (df = 33.2, t = −2.55, p = 0.02).
Secondary outcomes
The Adaptive Functioning Composite standard score
of the VABS showed no statistically significant week
by group effect (df = 51.2, t = −1.54, p = 0.09). A similar
finding was noted on the PLS-4, with no significant week
by group interaction observed (df = 31, t = −0.60, p = 0.6).
The CGI-I score was used as a dichotomous variable (1, 2:
responder, 3 to 7: non-responder), and no significant dif-
ference between groups was observed, p = 0.9.
Safety
There were no serious adverse events (SAEs) reported
during the study. Most adverse events reported were
mild to moderate in severity and are summarized in
Table 3. There was no statistically significant difference
between groups in either the severity of the most severe
adverse event (p = 0.3) or in the distribution of highest
probability of association with treatment (p = 0.9). There
were no statistically significant differences in the pre-
valence of adverse events across any of the event types
(p = 0.1 up to p > 0.9 across 18 event types). On inspec-
tion, there was great variability on both onset and dur-
ation of adverse events in both groups and no specific
patterns emerged.Exploratory
There was no statistically significant difference between
the treatment and control group (p > 0.9) for the CGI-I
focused on GI issues.
Omega-3 fatty acid levels were measured at baseline
and week 24. Baseline values were similar between the
two groups and there was no overlap between the distri-
butions of plasma levels between groups at week 24;
therefore, no further analyses were done to relate base-
line or change in omega-3 fatty acid level to change in
outcome.
In terms of cytokine levels, both negative correlations
(an increase in the cytokine level from baseline to week
24 correlated to a decrease in autism-related behaviors)
as well as positive correlations were observed; none of
which was considered significant when a Bonferroni
adjustment was applied (Additional file 3: Table S3).
Discussion
This is the first randomized controlled trial to our know-
ledge to study the efficacy and safety of omega-3 fatty
acids in children exclusively 5 years or younger, with
ASD. It also has the longest study duration (6 months),
allowing us to examine effects on functional outcomes.
Consistent with previous studies across age ranges, we
have no evidence for efficacy of omega-3 fatty acids on
core symptom domains. Given that the sample size is
Table 2 Efficacy table
Change from baseline Omega-3 change - placebo change P value
Omega-3 Placebo
PDDBI (negative change is an improvement)
Autism composite −4.5 (−8.5; −0.6) −6.4 (−10.2; −2.7) 1.9 (−3.3;7.0) 0.5
Sensory perception −2.0 (−5.0; 1.1) −3.7 (−6.7; −0.6) 1.7 (−2.4;5.9) 0.4
Social pragmatic −0.9 (−5.4; 3.5) −4.3 (−8.6; 0.1) 3.3 (−2.7;9.3) 0.3
Semantic pragmatic −0.4 (−5.1; 4.2) −1.7 (−6.3; 2.9) 1.2 (−5.2;7.6) 0.7
Social approacha −3.3 (−7.4; 0.8) −1.8 (−5.6; 2.0) −1.5 (−6.9;3.9) 0.6
Expressive languagea −3.5 (−7.3; 0.2) −1.5 (−5.0; 2.1) −2.1 (−7.1;3.0) 0.4
Ritualism/Resistance to change −3.8 (−6.8; −0.9) −6.4 (−9.3; −3.5) 2.6 (−1.5;6.6) 0.2
BASC (negative change is an improvement)
Internalizing 2.2 (−2.1; 6.6) −2.6 (−6.9; 1.7) 4.8 (−1.0;10.6) 0.1
Externalizing 3.2 (−0.5; 6.9) −3.0 (−6.6; 0.6) 6.2 (1.3;11.2) 0.02a
Functional communicationa −0.3 (−3.9; 3.3) −4.3 (−7.8; −0.8) 4.0 (−0.9;8.9) 0.1
Sociala −1.2 (−4.2; 1.9) −4.6 (−7.5; −1.7) 3.4 (−0.6;7.4) 0.1
VABS (positive change is an improvement)
Adaptive functioning composite 2.8 (0.2; 5.3) −0.2 (−2.6; 2.2) 3.0 (−0.4;6.4) 0.09
Motor 0.4 (−4.5; 5.4) −1.9 (−6.6; 2.9) 2.3 (−4.5;9.1) 0.5
Social −0.3 (−3.1; 2.5) 0.8 (−1.8; 3.4) −1.1 (−4.8;2.6) 0.6
Communication 1.6 (−1.5; 4.7) 0.9 (−2.0; 3.9) 0.6 (−3.5;4.8) 0.8
Daily living 5.5 (0.9; 10.0) −0.7 (−5.0; 3.6) 6.2 (0.01;12.3) 0.05
PLS (positive change is an improvement)
Total language score 0.7 (−2.7; 4.1) −0.6 (−3.7; 2.6) 1.3 (−3.1;5.7) 0.6
Primary/secondary outcome measures are in italics. All other measures are considered exploratory.
aItems are reversed so that negative change corresponds to an improvement across all PDDBI and BASC items.
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for the lack of difference between the groups. For that
reason, we explored whether values associated with
clinically meaningful change were included in the 95%
confidence interval for the omega-3 vs placebo difference
at 24 weeks, which was −3.3 to 7. Although there is no
published data on what constitutes meaningful change on
the autism composite of the PDDBI, extensive discussion
with the authors of the instrument suggested that 10
points or 1 standard deviation should be considered clin-
ically meaningful (personal communication, Ira Cohen,
2015). This value is not included in the above confidence
interval, which makes it unlikely that the lack of difference
between groups is due to sample size limitations. We also
found no evidence for efficacy of these compounds on lan-
guage acquisition, global improvement, or overall adaptive
skills over a 6-month period.
However, there was a statistically significant difference
in externalizing behaviors, with participants in the pla-
cebo group experiencing slight improvements and chil-
dren in the omega-3 group worsening over the course of
the study. This effect is peculiar in the context ofprevious studies, but is robust. There are several poten-
tial explanations for this. All of our participants were
5 years or younger; a group underrepresented in previ-
ous studies. As such, it is possible that omega-3 fatty
acids at the doses used produced externalizing behaviors
in this age group. Secondly, the majority of our partici-
pants were minimally verbal. As such, we considered the
possibility that potential GI distress, known to be associ-
ated with these supplements, may have been under-
reported by parents but captured as reports of external-
izing behaviors. The link between GI distress and exter-
nalizing behaviors in this population has been well
established [38]. However, there was no evidence of
increase in GI adverse events in the active group even
when the group was restricted to non-verbal individ-
uals. Of note though, 8/19 participants in the omega-
3 group had GI distress at baseline, and only 1/19 in
placebo group had GI distress at baseline. The possi-
bility that preexisting GI distress predisposes to exter-
nalizing behaviors cannot be ruled out. Of note, studies
in mostly older children have reported trends of improve-
ment in hyperactivity, as discussed in the background.
a. PDDBI c. PDDBI Difference
b. BASC d. BASC Difference
Figure 2 Omega-3 vs Placebo effects on the PDDBI and BASC-2. (a,b) Negative change reflects improvement, and (c,d) positive values favor
placebo. *Items are reversed so that negative change corresponds to an improvement across all PDDBI and BASC items.
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plored the effect of this intervention on hyperactivity as
measured by the BASC. There was no statistically signifi-
cant difference between groups and the trend favored pla-
cebo (df = 33.3, t = −1.79, p = 0.08).
Unlike previous reports [22], there were no con-
sistent or statistically significant correlations between
changes in primary outcome measures and changes in
cytokines during the study.
The non-overlapping distributions of the difference
between week 24 and baseline plasma levels of omega-3
fatty acids would suggest that any dietary intake of
omega-3 fatty acids was trivial compared to supplemen-
tation and that there was no cross contamination of the
active ingredient across groups; that is, participants onplacebo did not take omega-3 fatty acid supplements
without notifying study staff. As such, our lack of statis-
tically significant differences across domains could not
be due to placebo participants having accessed the active
ingredient available over the counter.
A limitation of this study stems from the relative pau-
city of outcome measures focusing on core autism symp-
tomatology for this age group. Although the PDDBI is
still relatively a new instrument, it is considered to hold
promise in this area [2], but its assay sensitivity is still
being established. The small sample size is the primary
limitation of the study. Given the number of participants,
we could only examine composite scores of various behav-
ioral and adaptive domains. However, there was no con-
sistent trend favoring the active ingredient.
Table 3 Adverse events
Omega-3 Placebo
Neuropsychiatric disorders Neuropsychiatric disorders
• Overactivity (3) • Decreased energy (2)










• Increase emotional lability (1)
• Increase irritability/anger/
aggression (10)
Sleep disturbances Sleep disturbances
• Initial insomnia (6) • Initial insomnia (4)
• Mid-cycle insomnia (6) • Mid-cycle insomnia (3)
• Early awakening (1) • Nightmares (1)






• Increased appetite (1) • Decreased appetite (3)
• Decreased appetite (7) • Abdominal pain (4)
• Decreased dietary variety (1) • Vomiting (3)
• Abdominal pain (6) • Diarrhea (9)




Eyes, ears, nose, teeth,
and throat
Eyes, ears, nose, teeth,
and throat
• Eye swelling (1) • Red eyes (1)
• Nearsightedness (1) • Nose bleed (3)
• Eye surgery (1) • Tonsillectomy (1)
• Earache (3)
Allergic Allergic
• Nasal congestion (2) • Nasal congestion (1)
• Cough (3) • Cough (4)
Urogenital disorders Urogenital disorders
• Day time wetting (1) • Pain on urination (1)
• Change in urine colour (1)
Musculoskeletal disorders Musculoskeletal disorders
• Muscle ache (1) • Left knee injury (1)
• Right leg internal rotation (2)





• Rash (10) • Rash (9)
• Eczema (2) • Eczema (4)
• Bruising (4)) • Bruising (2)
• Dry skin (1) • Dry skin (2)
• Flaky scalp (1)
Infections Infections
• Upper respiratory infections (23) • Upper respiratory
infections (24)
• Fever (4) • Fever (5)
• Ear infection (1) • Bronchiolitis (3)
• Gastroenteritis (1) • Ear infection (3)
• Skin infection (1) • Gastroenteritis (2)
• Skin infection (1)
• Hand mouth foot
disease (2)
• Roseola (1)
Serious adverse event: 0 Serious adverse event: 0
Numbers correspond to numbers of distinct incidents.
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These data do not support the hypothesis that supple-
mentation of 1.5 g of EPA + DHA in preschoolers with
ASD provides any efficacy related to core symptom do-
mains or adaptive function. Our data are not pertinent
to nutritional supplementation at levels recommended
by various health bodies to assure proper nutrition.
There is extensive data supporting adequate omega-3
fatty acid intake across age groups and for young
children in particular. Our data, however, would sug-
gest that much higher dosing typically given to chil-
dren with ASD and advocated as an autism-specific
supplementation does not facilitate skill acquisition in
this group and may be producing worsening externalizing
behaviors.Additional files
Additional file 1: Table S1. Schedule of assessments. Documents
which instrument utilize participant or parent/guardian as the informant,
the rater of the instrument, and the visit schedule of when each
instrument is administered.
Additional file 2: Table S2. Concomitant treatments. Number of
participants receiving each intervention per group, and average exposure
to each intervention per group.
Additional file 3: Table S3. Cytokine levels. Correlations between
change in cytokine levels and 0- to 24-week change in primary outcome
measures. A positive correlation corresponds to worsening behavior with
increasing cytokine levels.
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